Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 144 No. 0910 (2014)

Risk perception by healthcare professionals related to drug use during pregnancy: a Swiss survey

  • Chantal Csajka
  • Aurélie Jaquet
  • Ursula Winterfeld
  • Meyer Yvonne
  • Adrienne Einarson
  • Alice Panchaud
Cite this as:
Swiss Med Wkly. 2014;144:w13936


PRINCIPLE: Healthcare professionals’ (HCPs’) perception of risk associated with drug use in pregnancy may have an impact on the pharmacological treatment of some women. The aim of this study was to examine this risk perception in a sample of Swiss HCPs with a special focus on their knowledge and use of available specialised information sources.

METHOD: An online, French and German, questionnaire was e-mailed to 7,136 members of four Swiss professional societies (gynaecologists, paediatricians, midwives and pharmacists). The questionnaire was designed (a) to collect demographic characteristics, (b) to evaluate the frequency of use of several specialised sources of information on drugs in pregnancy in their daily practice, and (c) to examine the perception of risk associated with drug use during pregnancy.

RESULTS: A total of 1,310 questionnaires were collected (response rate of 18.4%). More than 80% of the respondent HCPs use the Swiss Drug Reference Book (Compendium) to assess the risk associated with drugs during pregnancy and are not aware of available specialised information sources (books, websites or information centres). Despite some disparities between HPCs, the risk related to drug intake was overall highly misperceived. Blinded reading of three product monographs in the Compendium was associated with an overestimated perception of risk (e.g., after reading the “paracetamol” monograph, 38% of the participants stated they would probably not advise the use of this drug to a pregnant patient).

CONCLUSION: Overall, an overestimation of the risk associated with drug use during pregnancy has been observed in our sample of HCPs, which might be related to the underuse of specialised information source among other factors. These findings evidenced the need for increased training for HCPs in order to optimise medication use during pregnancy. Further studies are needed to confirm these results and identify causes.


  1. Shahin I, Einarson A. Knowledge transfer and translation: examining how teratogen information is disseminated. Birth defects research Part A, Clinical and molecular teratology. 2011;91(11):956–61.
  2. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338(16):1128–37.
  3. Compendium Suisse des médicaments. In: Documed, ed.
  4. Feldman Y, Koren G, Mattice K, Shear H, Pellegrini E, MacLeod SM. Determinants of recall and recall bias in studying drug and chemical exposure in pregnancy. Teratology. 1989;40(1):37–45.
  5. Mitchell AA. Systematic identification of drugs that cause birth defects--a new opportunity. N Engl J Med. 2003;349(26):2556–9.
  6. Schaefer C, Spielmann H, Vetter K, Weber-Schöndorfer C. Arzneimittel in Schwangerschaft und Stillzeit. 8 ed: Urban & Fischer Verlag/Elsevier GmbH. 2012.
  7. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 9th ed: Lippincott Williams & Wilkins (LWW) 2011.
  8. Polifka JE, Faustman EM, Neil N. Weighing the risks and the benefits: a call for the empirical assessment of perceived teratogenic risk. Reprod Toxicol. 1997;11(4):633–40.
  9. Bonari L, Koren G, Einarson TR, Jasper JD, Taddio A, Einarson A. Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch Womens Ment Health. 2005;8(4):214–20.
  10. Koren G, Bologa M, Long D, Feldman Y, Shear NH. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol. 1989;160(5 Pt 1):1190–4.
  11. Nordeng H, Ystrom E, Einarson A. Perception of risk regarding the use of medications and other exposures during pregnancy. Eur J Clin Pharmacol. 2010;66(2):207–14.
  12. Koren G, Levichek Z. The teratogenicity of drugs for nausea and vomiting of pregnancy: perceived versus true risk. Am J Obstet Gynecol. 2002;186(5 Suppl Understanding):S248–52.
  13. Pole M, Einarson A, Pairaudeau N, Einarson T, Koren G. Drug labeling and risk perceptions of teratogenicity: a survey of pregnant Canadian women and their health professionals. J Clin Pharmacol. 2000;40(6):573–7.
  14. Behringer T, Rollman BL, Herbeck-Belnap B, Houck PR, Mazumdar S, Schwarz EB. Impact of physician counseling and perception of teratogenic risks: a survey of 96 nonpregnant women with anxiety. The primary care companion to CNS disorders. 2011;13(2).
  15. Bentur Y, Horlatsch N, Koren G. Exposure to ionizing radiation during pregnancy: perception of teratogenic risk and outcome. Teratology. 1991;43(2):109–12.
  16. Jasper JD, Goel R, Einarson A, Gallo M, Koren G. Effects of framing on teratogenic risk perception in pregnant women. Lancet. 2001;358(9289):1237–8.
  17. Koren G, Pastuszak A. Prevention of unnecessary pregnancy terminations by counselling women on drug, chemical, and radiation exposure during the first trimester. Teratology. 1990;41(6):657–61.
  18. Mazzotta P, Magee LA, Maltepe C, Lifshitz A, Navioz Y, Koren G. The perception of teratogenic risk by women with nausea and vomiting of pregnancy. Reprod Toxicol. 1999;13(4):313–9.
  19. Walfisch A, Sermer C, Matok I, Einarson A, Koren G. Perception of teratogenic risk and the rated likelihood of pregnancy termination: association with maternal depression. Can J Psychiatry. 2011;56(12):761–7.
  20. Widnes SF, Schjott J, Eide GE, Granas AG. Teratogenic risk perception and confidence in use of medicines in pairs of pregnant women and general practitioners based on patient information leaflets. Drug safety: an international journal of medical toxicology and drug experience. 2013;36(6):481–9.
  21. Goodwin J, Rieder S, Rieder MJ, Matsui D. Counseling regarding pregnancy--related drug exposures by family physicians in Ontario. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique. 2007;14(1):e58–69.
  22. Ratnapalan S, Bona N, Chandra K, Koren G. Physicians' perceptions of teratogenic risk associated with radiography and CT during early pregnancy. AJR Am J Roentgenol. 2004;182(5):1107–9.
  23. Sanz E, Gomez-Lopez T, Martinez-Quintas MJ. Perception of teratogenic risk of common medicines. Eur J obstet Gynecol Reprod Biol. 2001;95(1):127–31.
  24. Laupacis A, Sekar N, Stiell IG. Clinical prediction rules. A review and suggested modifications of methodological standards. JAMA: the journal of the American Medical Association. 1997;277(6):488–94.
  25. Centre de référence sur les agents tératogènes de Paris. Available from:
  26. Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie Berlin. Available from:
  27. L'emploi dans le domaine de la santé. In: statistique Ofdl, ed. 2007.
  28. Richoz C, Ayer A, Berchtold A, Richoz S. Record keeping by Swiss physiotherapists--a national survey of knowledge regarding legal requirements. Swiss Med Wkly. 2011;141:w13291.
  29. Allegra CJ, Hall R, Yothers G. Prevalence of burnout in the u.s. Oncology community: results of a 2003 survey. Journal of oncology practice / American Society of Clinical Oncology. 2005;1(4):140–7.
  30. Kuerer HM, Eberlein TJ, Pollock RE, Huschka M, Baile WF, Morrow M, et al. Career satisfaction, practice patterns and burnout among surgical oncologists: report on the quality of life of members of the Society of Surgical Oncology. Ann Surg Oncol. 2007;14(11):3043–53.
  31. Fletcher RH, Fletcher SW. Clinical epidemiology. the essentials. 4th ed 2005.
  32. Delaloye JF, Rousso P, Buclin T, De Grandi P, Vial Y, Hohlfeld P. Médicaments grossesse et lactation: Medecine & Hygiene. 2006.
  33. Ferreira E. Grossesse et allaitement: guide thérapeutique.: CHU Sainte-Justine 2007.
  34. Reprotox. Reprod Toxicol. 2013.

Most read articles by the same author(s)